A 62-year-old postmenopausal woman with a T-score of −3.2 at the femoral neck presents for osteoporosis management. She has no renal impairment and normal serum calcium. The physician explains that the pathway marked **C** in the diagram (RANKL → RANK signaling) is the key mechanism driving her bone loss. To inhibit this pathway and reduce fracture risk, which of the following agents would be most appropriate for this patient?

Explanation

## Why Denosumab is right Denosumab is a monoclonal antibody that directly binds RANKL, acting as a soluble decoy receptor (mimicking osteoprotegerin, marked **D**) to block the RANKL → RANK interaction shown in pathway **C**. By inhibiting this critical signaling axis, denosumab potently suppresses osteoclast differentiation and activation, thereby reducing bone resorption. It is specifically indicated for postmenopausal osteoporosis at high fracture risk and is administered as 60 mg subcutaneously every 6 months. The question explicitly anchors on pathway **C** (RANKL → RANK signaling), and denosumab is the only agent that directly targets this mechanism. (Guyton & Hall 14e Ch 80; KD Tripathi 9e Ch 24) ## Why each distractor is wrong - **Alendronate**: A bisphosphonate that inhibits osteoclast function by blocking farnesyl pyrophosphate synthase and promoting osteoclast apoptosis—it acts downstream of the RANKL-RANK pathway, not on pathway **C** itself. While effective for osteoporosis, it does not directly block RANKL-RANK signaling. - **Raloxifene**: A selective estrogen receptor modulator (SERM) that increases OPG expression indirectly, but does not directly inhibit the RANKL → RANK signaling pathway **C**. It is less potent than denosumab for high-risk fracture patients. - **Teriparatide**: A recombinant PTH analog that stimulates osteoblast activity and bone formation—it acts on the anabolic side of bone remodeling, not on the RANKL-RANK pathway **C**. It does not directly inhibit osteoclast maturation or activation. **High-Yield:** Denosumab directly blocks RANKL-RANK signaling (pathway **C**) by acting as a decoy receptor; it is the only agent that mechanistically targets this specific axis and is preferred in high-risk postmenopausal osteoporosis. Remember: rebound vertebral fractures can occur if denosumab is discontinued without transition to a bisphosphonate. [cite: Guyton & Hall 14e Ch 80; KD Tripathi 9e Ch 24]